March 30, 2019
March 30, 2019
Local breakthrough research has shown the capability of cells to eliminate malignant tumors induced by hepatitis B after cellular reprogramming.
In this study, autologous T cells from two patients with recurrence of HCC post liver transplantation were engineered to express TCRs specific for epitopes expressed from HBV-DNA in patients’ metastases. The treatment was well tolerated without notable adverse events in these two patients. Importantly, in one patient, 5 of 6 pulmonary metastases decreased in volume during the 1-year period of T-cell administration. This encouraging clinical data was published in Gastroenterology (Tan et al,2019).
The research was conducted in collaboration with Duke-National University ofSingapore School of Medicine (Duke-NUS), Singapore General Hospital, and LionTCR. - Lianhe Zaobao
Lion TCR Announces Data Presentation for its lead T-cell product, LioCyx-M at EASL Digital Liver Cancer Summit 2021
HSA approval for Phase 1 IND clinical trial for Lion TCR’s lead product LioCyx-M to characterize changes in liver cancer tumor microenvironment
Lion TCR presents two abstracts of Phase 1 clinical trial data for lead product LioCyx-M at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Companion diagnostic assay for personalised immunotherapy for HBV-related liver cancer featured in A*STAR GIS website
Singapore’s first clinical trial approval for T cell engineered (TCR) immunotherapy for treatment of Liver cancer
Lion TCR receives US$ 20 million to fund its personalized T cell therapy clinical trials against Liver cancer
Scientific Founder, Prof. Antonio Bertoletti and Scientific Consultant, Dr Anthony Tanoto Tan of Lion TCR were awarded the SingHealth Duke-NUS Research Award 1st Prize 2018
US FDA grants Lion TCR two orphan drug designations of T cell therapy against Hepatocellular Carcinoma
New publication – Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient